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Background: Overactive bladder (OAB)/ storage lower urinary tract symptoms (LUTS) have a high prevalence
affecting up to 90% of men over 80 years. The role of sufficient therapies appears crucial. In the present review, we
analyzed the mechanism of action of tolterodine extended-release (ER) with the aim to clarify its efficacy and safety
profile, as compared to other active treatments of OAB/storage LUTS.
Methods: A wide Medline search was performed including the combination of following words: “LUTS”, “BPH”,
“OAB”, “antimuscarinic”, “tolterodine”, “tolterodine ER”. IPSS, IPSS storage sub-score and IPSS QoL (International
Prostate Symptom Score) were the validated efficacy outcomes. In addition, the numbers of urgency episodes/24 h,
urgency incontinence episodes/24 h, incontinence episodes/24 h and pad use were considered. We also evaluated
the most common adverse events (AEs) reported for tolterodine ER.
Results: Of 128 retrieved articles, 109 were excluded. The efficacy and tolerability of tolterodine ER Vs. tolterodine IR
have been evaluated in a multicenter, double-blind, randomized placebo controlled study in 1529 patients with
OAB. A 71% mean reduction in urgency incontinence episodes was found in the tolterodine ER group compared to
a 60% reduction in the tolterodine IR (p < 0.05). Few studies evaluated the clinical efficacy of α-blocker/tolterodine
combination therapy. In patients with large prostates (prostate volume >29 cc) only the combination therapy
significantly reduced 24-h voiding frequency (2.8 vs. 1.7 with tamsulosin, 1.4 with tolterodine, or 1.6 with placebo).
A recent meta-analysis evaluating tolterodine in comparison with other antimuscarinic drugs demonstrated that
tolterodine ER was significantly more effective than placebo in reducing micturition/24 h, urinary leakage episodes/
24 h, urgency episodes/24 h, and urgency incontinence episodes/24 h. With regard to adverse events, tolterodine
ER was associated with a good adverse event profile resulting in the third most favorable antimuscarinic. Antimuscarinic
drugs are the mainstay of pharmacological therapy for OAB / storage LUTS; several studies have demonstrated that
tolterodine ER is an effective and well tolerated formulation of this class of treatment.
Conclusion: Tolterodine ER resulted effective in reducing frequency urgency and nocturia and urinary leakage in male
patients with OAB/storage LUTS. Dry mouth and constipation are the most frequently reported adverse events.
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Lower Urinary Tract Symptoms (LUTS) have a high
prevalence affecting up to 90% of men over 80 years [1].
The term LUTS comprises a large group of symptoms
usually divided into storage LUTS (daytime urinary
frequency, nocturia, urgency, urinary incontinence),
voiding LUTS (slow stream, splitting or spraying, inter-
mittency, hesitancy, straining, terminal dribble), and
post micturition LUTS (sensation of incomplete empty-
ing, post-micturition dribble) [2].
In men, LUTS may be associated with benign prostatic
obstruction (BPO) typically resulting from benign pros-
tatic hyperplasia (BPH) or benign prostatic enlargement
(BPE) [3]. Approximately half of men with histological
BPH develop BPE but only 25–50% of these men have
LUTS [4,5].
OAB and storage LUTS are defined as the presence of
urinary urgency, usually accompanied by frequency and
nocturia, with or without urinary incontinence, in ab-
sence of urinary tract infection or other urethro-vesical
dysfunctions [2]. Storage LUTS are generally a chronic
condition, with a prevalence ranging from 10% to 26%
[6,7]. Male storage symptoms could be caused by blad-
der dysfunction (like detrusor overactivity or detrusor
impaired contractility), BPO (often caused by BPE) or by
a combination of both bladder dysfunction and BPO
[8,9]. In that scenario, the role of targeted therapies ap-
pears crucial. In order to obtain clinical relief of storage
LUTS, an extensive counseling of patients is mandatory
to evaluate all the possible treatments and their expected
results since the lack of efficacy and the presence of
bothering adverse events (AEs) can reduce compliance.
Behavioral therapies should be offered as first line treat-
ment for all patients with storage LUTS. Their goal is to
relieve bladder symptoms by changing voiding habits
(bladder training, delayed voiding) or by improving control
of urge suppression and urethral occlusion (PFMT). Never-
theless the gold standards of pharmacological therapy
are antimuscarinic agents such as oxybutynin, tolterodine,
fesoterodine, darifenacin, solifenacin, or trospium [10].
Antimuscarinics (m-cholinoceptor antagonists) espe-
cially block specific receptors at the level of the bladder
(M2 and M3 receptors on smooth muscle cells of the
detrusor) in a more or less selective manner, thereby re-
ducing involuntary bladder contractions or altering con-
traction thresholds. Antimuscarinics act mainly during
the urinary storage phase and decrease the activity of af-
ferent bladder nerves [11] resulting in decreased urgency
and increased bladder capacity. However, muscarinic re-
ceptors are also found in other parts of the body, includ-
ing the brain, heart, gut, salivary glands, and tear ducts.
First marketed antimuscarinics were limited by adverse
effects, resulting in poor patient compliance and discon-
tinuation of treatment [12].Oxybutynin was the first antimuscarinic agent, used
since the mid-70s, for the treatment of overactive blad-
der (OAB)/bladder storage symptoms [13]. Oxybutynin
immediate release (IR) has proven efficacy for the condi-
tion [14]. However, it has a significant incidence of per-
ipheral anti-muscarinic adverse events such as dry
mouth, constipation, tachycardia, paralysis of accommo-
dation and central nervous system side effects (cognitive
dysfunction or delirium), resulting in poor compliance
and early discontinuation of therapy in a large number
of patients [12,13].
More than fifteen years ago, tolterodine was developed
with the aim of obtaining a better efficacy/adverse event
profile and improving the compliance of patients com-
pared to other antimuscarinic drugs. It is lesser lipid
(soluble) than oxybutynin and crosses the blood–brain
barrier to a lesser extent. Tolterodine is non-selective
with respect to the muscarinic receptor sub-types but, as
shown by data obtained from animals and healthy volun-
teers in the first clinical trials, showed a greater, more
rapid and longer lasting effect on the bladder than on
salivary glands in vivo [15-17].
Patient tolerability represents a fundamental parameter
for the administration of antimuscarinic agents. Given the
established role of frequency-dose and patient compliance
and its potential effect on tolerability and efficacy, an ex-
tended release (ER) formulation was developed for several
antimuscarinics. In a large systematic review and meta-
analysis [18], all the comparisons among IR (drug intake
2–3 times/day) and ER formulations (drug intake once/
day) showed advantages for the latter, either in terms of
efficacy or safety.
Few studies investigated the effects of antimuscarinic
drugs on male patients with bladder outlet obstruction
and OAB/bladder storage symptoms and the results of the
use of antimuscarinic agents as monotherapy were con-
flicting. Starting in 1994, the approach of combination
therapy with α-blockers and antimuscarinics has become
increasingly popular [19]. Earliest report of Athanasopou-
los et al. [20] on the effects of tolterodine 2 mg twice daily
combined with tamsulosin 0.4 mg once daily compared
with tamsulosin alone in 25 patients showed a better QoL
only in the combination therapy group with no acute urin-
ary retention. As a result, there has been a growing inter-
est on the use of antimuscarinics in male LUTS/BPH.
Antimuscarinics have been increasingly used in clinical
practice - with caution and regular re-evaluation - in
particular for selected patients with moderate to severe
LUTS who have predominant bladder storage symptoms
and do not have elevated post-void residual urine vol-
umes [21,22]. In the present review we analyzed in detail
the mechanism of action of tolterodine ER and its over-
all safety and efficacy in the treatment of male bladder
storage LUTS.
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A wide Medline search was performed including the com-
bination of following search terms: “LUTS”, “BPH”, “OAB”,
“antimuscarinic”, “tolterodine”, “tolterodine ER”. No tem-
porary limits were adopted. IPSS, IPSS storage sub-score
and IPSS QoL (International Prostate Symptom Score)
were the validated efficacy outcomes. In addition, the num-
bers of urgency episodes/24 h, urgency incontinence epi-
sodes/24 h, incontinence episodes/24 h and pad use were
considered. We also evaluated the most common adverse
events (AEs) reported for tolterodine ER in selected studies.
Results
Out of 128 retrieved articles, 109 were excluded for
missing or incomplete data, deficiency in methodology
(several biases not included), assessment of clinical out-
comes without validated instruments. the total flowchart
of literature searches is summarized in Figure 1.
Mechanism of action of tolterodine
Muscarinic receptors
Five sub-types of muscarinic receptors are presented in
the human tissues: even if all these receptors can be foundFigure 1 Flowchart of literature searches according to PRISMA statemin several tissues, including epithelial cells of the bladder
and the salivary glands and nerve cells of the central or
peripheral nervous systems, the M2 and M3 are predomin-
antly expressed in detrusor smooth muscle cells [23]. De-
trusor contractions are stimulated by the activity of
acetylcholine on muscarinic receptors on smooth muscles
cells of the bladder.
Tolterodine is a competitive muscarinic receptor an-
tagonist with relative functional selectivity for bladder
muscarinic receptors. It is metabolized in microsomes of
the human liver by cytochromes P450 (CYP2D6 and
CYP3A4) to two primary metabolites: 5-hydroxymethyl
tolterodine (5-HMT) (labcode DD 01; PNU-200577) and
N-dealkylated tolterodine [23,24]. With the exception of
5-HMT, metabolites of tolterodine are not considered to
contribute to the therapeutic effect.
In vitro studies in guinea-pig detrusor strips [25] showed
a simple competitive blockade of the bladder muscarinic
receptors in a concentration-dependent manner after
carbachol-induced contractions. Tolterodine was equipo-
tent to oxybutynin and acted as an effective and competi-
tive muscarinic receptor antagonist also in human isolated
urinary bladder. Radioligand binding studies in tissueent.
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expressed as the dissociation constants (ki), for tolterodine
in human bladder were comparable to those in the
guinea-pig bladder [25].
Selectivity profile
The binding affinities determined in the bladder were
similar to those in the heart, which can be assumed to
contain only muscarinic M2 receptors [25].
Tolterodine and 5-HMT show functional selectivity
for the bladder over the salivary glands in vivo. In the
anaesthetized cats, intravenous injection of tolterodine
and 5-HMT resulted in dose-dependent inhibition of
acetylcholine-induced urinary bladder contractions and
electrically induced salivation. The effect on urinary
bladder contractions occurred at significantly lower
doses than the effect on salivary secretion, showing fa-
vorable tissue selectivity [25-27]. In 2008 Olshansky
et al. showed an increase in mean heart rate per 24 hours
of ≥5 beats per minute higher with tolterodine than with
placebo (p = 0.0114) [28]. Neither oxybutynin nor tolter-
odine showed clinically significant effects on the heart
rate [25,27].
The selectivity profiles in vivo were reflected in the
radioligand binding studies. Thus, the affinity profile of
tolterodine (cerebral cortex ≥ heart ≈ urinary bladder >
parotid gland) differed from those of oxybutynin (cere-
bral cortex ≈ parotid gland > heart ≈ urinary bladder).
Pharmacokinetics
The pharmacokinetic properties of tolterodine are influ-
enced by the CYP2D6 polymorphism. The lack or
strongly reduced activity of this liver enzyme character-
izes poor metabolizers. In these individuals, the active
metabolite 5-HMT cannot be formed and the pharmaco-
logical effects are mediated exclusively by tolterodine. As
shown in a clinical study by Brynne et al. [29], toltero-
dine was rapidly absorbed in both extensive and poor
metabolizer, and the pharmacodynamic effects of tolter-
odine were not generally influenced by metabolic pheno-
type. Thus, the same dosage can be used irrespective of
CYP2D6 phenotype.
Pharmacokinetic equivalence was demonstrated be-
tween IR tolterodine tablets 2 mg twice daily and ER
capsule formulation of tolterodine 4 mg once daily
(AUC24). In addition, tolterodine ER resulted in less
serum drug level fluctuation and sustained drug release
over 24 hours [27]. This translates into more constant
serum concentrations and, in theory, also into better tol-
erability for patients.
The clearance of tolterodine was considerably lower in
patients with liver cirrhosis or impaired renal function
[creatinine clearance 10–30 ml/min (0.6 to 1.8 L/h)]
compared to healthy volunteers [30].Discussion
Safety and efficacy of tolterodine Er
Tolterodine ER vs. Tolterodine IR
Tolterodine intermediate release (IR) was firstly devel-
oped and tested in several randomized, double-blind,
placebo controlled study which led to drug approval by
the FDA in 1998. The efficacy and tolerability of toltero-
dine IR and oxybutynin IR were found to be comparable
[14]. Dry mouth was the only adverse event that oc-
curred significantly more often in patients treated with
tolterodine IR (1 mg bid, 30%; 2 mg bid, 48%) in com-
parison to patients of the placebo group; however, only
3% of the tolterodine IR treated subjects withdrew from
treatment because of dry mouth [31].
Regardless of the positive results of the registration
trials and confirmation of the excellent efficacy in rando-
mised phase IV studies [32-34], Pfizer laboratories devel-
oped an extended release (ER) formulation (approved by
the FDA in 2000) to improve patient compliance and to
decrease the dry mouth rate which was thought to be
dependent from the peak plasma levels of the drug. Tol-
terodine ER uses a drug delivery system that contains
soluble microspheres. The drug is slowly released as the
outer layer of the microsphere dissolves, leading to con-
sistent delivery of drug over a 24-hour period [35].
The efficacy and tolerability of tolterodine ER have
been evaluated in a multicenter, double-blind, random-
ized placebo controlled study in 1529 patients with OAB
[13,36]. A significant clinical advantage in terms of clin-
ical efficacy and tolerability was associated with toltero-
dine ER treatment. A 71% mean reduction in urgency
incontinence episodes was found in the tolterodine ER
group compared to a 60% reduction in the tolterodine
IR group (p < 0.05). The incidence of dry mouth was
23% for tolterodine ER versus 30% for tolterodine IR.
The overall rate of dry mouth was 23% lower with tolter-
odine ER than with tolterodine IR. The incidence of
other adverse events such as dizziness (ER 2% vs. IR
2%), constipation (ER 7% vs. IR 6%) and somnolence (ER
3% vs. IR 3%) were similar between the treatment groups
and comparable with placebo. This pivotal study sug-
gested an improved clinical advantage of tolterodine ER
over the IR formulation of the drug in terms of efficacy
and tolerability.
Tolterodine in combination therapies for OAB/LUTS
The theoretical concern about a negative effect on post-
void residual urine or even urinary retention has influ-
enced the use of antimuscarinics for the management of
storage LUTS in male patients independent of studies
showing no increased risk of urinary tract retention in
patients with benign prostatic obstruction. The com-
bined use of antimuscarinics and other drugs currently
available for LUTS, including α-blockers, 5α-reductase
Table 1 Comparison of tolterodine ER versus other
antimuscarinics as reviewed in the 2012 AHRQ review
[49]
Experimental drug
versus standard drug
No. of
studies
Patients Relative risk
(95% CI)
Efficacy (cure of UI)
Fesoterodine vs tolterodine ER 2 3312 1.1 (1.04-1.16)
Oxybutynin ER vs tolterodine ER 3 947 1.11 (0.94-1.16)
Solifenacin vs tolterodine ER 1 1177 1.2 (1.08-1.34)
Discontinuation due to adverse events
Solifenacin vs tolterodine ER 3 2755 1.28 (0.86-1.91)
Fesoterodine vs tolterodine ER 4 4440 1.54 (1.21-1.97)
Efficacy was defined as the achievement of urinary continence.
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duction of ß3-agonists has recently been investigated to
overcome these limitations [37-40].
Few studies have evaluated the clinical efficacy of α-
blocker/tolterodine combination therapy [37-39]. The
majority are add-on studies, in which tolterodine has
been added to an existing α1-blocker therapy. The “Tol-
terodine and Tamsulosin in Men With LUTS Including
OAB: evaluation of Efficacy and Safety” (TIMES) study
showed that patients treated with tolterodine/tamsulosin
combination therapy, but not with tamsulosin, toltero-
dine or placebo alone, had a significant treatment benefit
as defined by the patient perception questionnaire (80%
vs. 71%, 65%, and 62%, respectively) [37,39]. At the end
of the study period (12 weeks), only combination ther-
apy significantly improved total IPSS and QoL as well
as the IPSS storage sub-score. The TIMES study also
identified a subgroup of patients with a PSA value
<1.3 ng/ml or prostate volume <29 ml who also signifi-
cantly profited from tolterodine monotherapy with re-
gard to storage symptom reduction [37,39]. In patients
with large prostates (prostate volume >29 cc) only the
combination therapy significantly reduced 24-h voiding
frequency (2.8 vs. 1.7 with tamsulosin alone, 1.4 with
tolterodine alone, or 1.6 with placebo). Adverse events
of antimuscarinics (e.g. dry mouth or constipation) oc-
curred in the combination therapy group more often
than in patients receiving α1-blocker monotherapy.
There was no significant or clinically relevant increase in
post-void residual urine or acute urinary retention when
the combination treatment arm was compared with
mono-therapy of the individual drugs [39].
Another investigational combination therapy with tolter-
odine ER was with 5α-reductase inhibitors. In particular,
Chung et al. demonstrated that in men with persistent
OAB symptoms after at least 6 months of treatment with
dutasteride the addition of tolterodine ER allowed to sig-
nificantly reduce frequency and urgency, such as severe
OAB episodes and night time voiding (nocturia). Storage
LUTS (IPSS storage sub-score) were remarkably reduced
from 9.8 to 4.5 (p < 0.001). Regarding tolerability, 7.5% of
men experienced dry mouth, but no patient developed
urinary retention [40].
The efficacy and safety of tolterodine in combination
therapies was reviewed by Athanasopoulos et al. in 2011,
concluding that combination therapy was effective and
the risk of urinary retention was minimal [41].
Mirabegron, a novel ß3-adrenoceptor agonist, has re-
cently been approved for the treatment of OAB symp-
toms and is the first of a new class of compounds with a
mechanism of action that is different from antimuscari-
nic agents. Mirabegron represents a new option for the
management of OAB, has a comparable efficacy and a
better tolerability when compared to tolterodine 4 mgER in a large clinical trial dataset in OAB/storage LUTS
patients. However, further studies should assess its long
term safety and efficacy and the possible role in specific
group of patients as male patients with LUTS and be-
nign prostatic obstruction, either alone or in combin-
ation with antimuscarinics (e.g. tolterodine ER) [42,43].
Tolterodine ER vs. other antimuscarinics
Since its introduction in clinical practice, tolterodine
has been the active comparator in several studies. The
first comparator trial using tolterodine ER was the
“Overactive Bladder: Performance of Extended Release
Agents” (OPERA) study [44] which compared the effi-
cacy and tolerability of tolterodine ER (4 mg daily) and
oxybutynin (10 mg daily). No significant difference was
observed in the number of urgency incontinence epi-
sodes (tolterodine 20.9% vs. oxybutynin 26.7%) or the
total dry rate (tolterodine 16.8% vs. oxybutynin 23%).
Regarding adverse events, the most common side ef-
fect in each group was dry mouth, with 29.7% of the pa-
tients receiving oxybutynin vs. 22.3% of those receiving
tolterodine (p = 0.02). Other adverse events were similar
in magnitude and frequency in both groups [18,35]. A
recently published study tested the efficacy and tolerabil-
ity of tolterodine ER versus solifenacin [45]. The STAR-
study compared flexible dosing of solifenacin versus tol-
terodine 4 mg in the primary outcome criteria (change
in number of micturictions per 24 hours). Solifenacin
flexible dosing proved to be superior to tolterodine ER
in reducing the numbers of urgency episodes/24 h
(−2.85 vs. −2.42), urgency incontinence episodes/24 h
(−1.42 vs. −0-83), incontinence episodes/24 h (−1.60 vs.
1–11), and pad use (−1.72 vs. −1.19). Dry mouth and
constipation were significant more common in the soli-
fenacin arm (18.2 vs. 14.5% and 3.0 vs. 1.2%, respect-
ively), although they were mainly of mild to moderate
severity [18,45].
In 2008 Chapple et al. compared the antimuscarinic
fesoterodine 4 mg or fesoterodine 8 mg once daily to
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active control arm tolterodine ER 4 mg [46]. Fesotero-
dine 8 mg outperformed tolterodine 4 mg with regard to
the median change from baseline in number of UUI
episodes (p < 0.05) and volume voided per micturition
(p < 0.05), while similar efficacy was shown for fesotero-
dine 4 mg and tolterodine 4 mg. Fesoterodine 4 mg and
tolterodine ER 4 mg had a similar safety profile, while fes-
oterodine 8 mg was associated with significantly higher
rates of dry mouth (p < 0.0001) and dry eyes (p = 0.02)
compared to tolterodine 4 mg [18]. In 2013 Ginsberg et al.
[47] compared the efficacy of fesoterodine 8 mg vsFigure 2 Forest plots of efficacy and safety after IR and ER tolterodin
3c: dry mouth; 3d: headache. (License number 3340911442671 of Mar 2, 20tolterodine 4 mg ER for OAB symptoms in terms of
patient-reported outcomes in both men and women, sup-
porting the superiority of fesoterodine 8 mg over toltero-
dine 4 mg ER in improving severe urgency and symptom
bother in men.
The EAU Guidelines on Urinary Incontinence recently
evaluated and reported data from the Agency for
Healthcare Research and Quality (AHRQ) review which
included a specific section addressing comparisons of
antimuscarinic drugs [48,49] (Table 1). They concluded
that there was no evidence that any one antimuscarinic,
including tolterodine ER, improved quality of life moree. 3a: micturitions/24 Hrs; 3b: volume voided per micturition;
14 between Elsevier and Dr. G. Novara).
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for the superiority of one antimuscarinic agent over an-
other for the overall efficacy or discontinuation rate.
However, the recently published studies comparing tol-
terodine with fesoterodine have not been included in
this analysis.
A recent network meta-analysis evaluating tolterodine
in comparison with other antimuscarinic drugs demon-
strated that tolterodine ER was significantly more effect-
ive than placebo in reducing micturition/24 h (−0.76;
p <0.001), urinary leakage episodes/24 h (−0.36; p <0.001),
urgency episodes/24 h (−0.77; p <0.001), and urgency in-
continence episodes/24 h (−0.34; p <0.001) [48]. With re-
gard to adverse events, the same article demonstrated that
tolterodine ER was associated with a good adverse event
profile resulting in the third most favorable antimuscarinic
out of 21 analyzed antimuscarinic drugs, following oxybu-
tynin topical gel 100 mg/g per day and solifenacin 5 mg
per day [50] (Figure 2).Conclusions
Tolterodine is an effective muscarinic receptor antagon-
ist, with a receptor affinity comparable to oxybutynin in
the bladder, and a remarkably lower affinity than oxybu-
tynin in the parotid gland. Immediate-release tablets
2 mg twice daily and extended-release tablets 4 mg once
daily have a comparable pharmacokinetic profile.
Tolterodine ER resulted effective in reducing frequency
urgency and nocturia and urinary leakage in patients with
OAB/storage LUTS. Dry mouth and constipation are the
most frequently reported adverse events. The good safety
profile, which allow to minimize treatment withdrew, and
the adequate effectiveness in the management of storage
LUTS, are the strengths of Tolterodine ER.
Further RTCs are needed to identify the best candi-
dates for the treatment with tolterodine ER and to tailor
promising combination therapies with other drugs cur-
rently available for male LUTS.Competing interests
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